Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Studied in peopleStub

ACE-083

Locally acting follistatin-based protein

A follistatin-based fusion protein designed to act in the injected muscle; its trials in muscular dystrophy were discontinued.

Reconstitution calculator

At a glance

Studied in people

There are published studies in people. It is not a licensed medicine in the United States or the European Union.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies: ACE-083

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

5
papers on PubMed
4
of them in people
2
randomized trials
1
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on ACE-083 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of ACE-083; no amount here is a recommendation.

ACE-083: on PubMed

What PubMed held for ACE-083 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

5
papers
4
in humans
2
clinical trials
2
randomized trials
2012: 0 papers122013: 0 papers2014: 0 papers142015: 0 papers2016: 0 papers162017: 0 papers2018: 1 papers182019: 1 papers2020: 1 papers202021: 0 papers2022: 2 papers222023: 0 papers2024: 0 papers242025: 0 papers2026: 0 papers so far26
Papers per year, 2012 to 2026. The most in one year: 2.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Locally acting ACE-083 increases muscle volume in healthy volunteers

    Randomized trialGlasser CE, Gartner MR, Wilson D, et al. Muscle & nerve, 2018. PMID 29486514

  2. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy

    Randomized trialStatland JM, Campbell C, Desai U, et al. Muscle & nerve, 2022. PMID 35428982

  3. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

    StudyThomas FP, Brannagan TH 3rd, Butterfield RJ, et al. Neurology, 2022. PMID 35545446

  4. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease

    StudyPearsall RS, Davies MV, Cannell M, et al. Scientific reports, 2019. PMID 31388039

  5. [Research advance of underlying pathogenesis and target therapies in Charcot-Marie-Tooth disease type 1A]

    ReviewCao W, Zhang R Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2020. PMID 32335891

Search used: ("ACE-083"[tiab]). Run it on PubMed

Research links

Also in Muscle and bone